Efficacy and Safety Concerns with Sn-Mesoporphyrin as an Adjunct Therapy in Neonatal Hyperbilirubinemia: A Literature Review.
Journal
International journal of pediatrics
ISSN: 1687-9740
Titre abrégé: Int J Pediatr
Pays: Egypt
ID NLM: 101517077
Informations de publication
Date de publication:
2022
2022
Historique:
received:
22
04
2022
accepted:
29
06
2022
entrez:
28
7
2022
pubmed:
29
7
2022
medline:
29
7
2022
Statut:
epublish
Résumé
Neonatal hyperbilirubinemia is a frequently observed clinical situation that, sometimes, may result in complications ranging from mild neurodevelopment impairment to serious outcome of kernicterus. The rationale logic of heme oxygenase enzyme inhibition to lower bilirubin levels is intriguing. In compliance with that rationale, metalloporphyrin was discovered. After successful results in in-vitro and animal studies, tin mesoporphyrin is now under phase II clinical trial to test for preventive and therapeutic efficacy in unconjugated hyperbilirubinemia. This review evaluates in-vitro studies, animal studies, and clinical trials for the efficacy and safety of tin analogues of metalloporphyrin. Few alternatives to metalloporphyrins are also available, synchronizing with the same rationale logic of inhibition of bilirubin production, which need further research.
Identifiants
pubmed: 35898803
doi: 10.1155/2022/2549161
pmc: PMC9314175
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
2549161Informations de copyright
Copyright © 2022 Prakar Poudel and Sudhir Adhikari.
Déclaration de conflit d'intérêts
The authors declare that there is no conflict of interest regarding the publication of this paper.
Références
Pediatrics. 2001 Dec;108(6):1374-7
pubmed: 11731664
Science. 1982 Sep 24;217(4566):1250-2
pubmed: 6896768
Biochem J. 1980 Nov 15;192(2):637-48
pubmed: 6894538
Annu Rev Pharmacol Toxicol. 1997;37:517-54
pubmed: 9131263
Pediatrics. 1989 Dec;84(6):1031-7
pubmed: 2531365
J Clin Invest. 1984 Jul;74(1):142-9
pubmed: 6547455
Pediatrics. 2004 Jul;114(1):e130-53
pubmed: 15231986
Proc Natl Acad Sci U S A. 1981 Oct;78(10):6466-70
pubmed: 6947237
Pediatr Res. 1993 Feb;33(2):195-200
pubmed: 8433895
Pediatr Res. 2006 May;59(5):667-72
pubmed: 16627879
Pharmacology. 1998 Mar;56(3):158-64
pubmed: 9532616
Pediatrics. 1995 Apr;95(4):468-74
pubmed: 7700742
Pediatr Res. 2012 Aug;72(2):161-8
pubmed: 22580722
Pediatrics. 1995 Jun;95(6):942-4
pubmed: 7761229
Pediatrics. 1999 Jan;103(1):1-5
pubmed: 9917431
Arch Biochem Biophys. 1987 May 15;255(1):64-74
pubmed: 3592668
J Perinatol. 2012 Nov;32(11):899-900
pubmed: 23128060
Pediatrics. 2001 Jul;108(1):25-30
pubmed: 11433050
J Perinatol. 2022 Jan;42(1):110-115
pubmed: 34635771
Pediatrics. 2010 Feb;125(2):405-9
pubmed: 20100744
Dev Pharmacol Ther. 1990;14(3):187-92
pubmed: 2364856
J Pharmacol Exp Ther. 1991 Jun;257(3):1109-13
pubmed: 2046022
J Biol Chem. 1969 Dec 10;244(23):6388-94
pubmed: 4390967
J Perinatol. 2011 Apr;31 Suppl 1:S35-41
pubmed: 21448202
Eur J Pediatr. 1990 Jan;149(4):278-9
pubmed: 2303077
Pediatr Res. 1984 Aug;18(8):728-30
pubmed: 6548009
Proc Natl Acad Sci U S A. 1979 Oct;76(10):5331-5
pubmed: 291950
Can J Physiol Pharmacol. 1996 Mar;74(3):278-85
pubmed: 8773407
J Inorg Biochem. 2010 Mar;104(3):324-30
pubmed: 19917515
J Biol Chem. 1977 Aug 25;252(16):5900-3
pubmed: 18477
J Biol Chem. 1982 Jul 10;257(13):7778-85
pubmed: 6806282
Pediatrics. 1998 May;101(5):E1
pubmed: 9565434
Pediatrics. 1992 Feb;89(2):175-82
pubmed: 1734381
J Clin Invest. 1986 Mar;77(3):971-6
pubmed: 3753986
Dev Pharmacol Ther. 1990;15(2):112-24
pubmed: 2078972
Pharm Res. 1993 May;10(5):715-21
pubmed: 8321837
Biol Neonate. 2006;89(3):139-46
pubmed: 16205054
Pediatrics. 1994 Jan;93(1):1-11
pubmed: 8265301
J Clin Invest. 1986 Feb;77(2):335-9
pubmed: 3511095
J Perinatol. 2016 Jul;36(7):533-9
pubmed: 26938918
Blood. 1983 May;61(5):1011-3
pubmed: 6687556
Proc Natl Acad Sci U S A. 1985 Feb;82(3):896-900
pubmed: 3856238
Bioorg Med Chem. 2007 May 1;15(9):3225-34
pubmed: 17339115